Haemonetics Corporation (HAE) stock analysis

HAE · Haemonetics Corporation

Latest recorded price: USD 121.35

Model-estimated fair value: USD 41.43. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Medical Devices

At $121.35, HAE trades 192.9% above the model's base-case value of $41.43. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $27.27 in the conservative case and $59.02 in the optimistic case, with a valuation confidence score of 75/100. About 77% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2026 figures: revenue growth 13.6%, free cash flow margin 19.5%, ROIC 7.0%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare